Prevention of CNS relapse in diffuse large B-cell lymphoma

The Lancet Oncology

Volumn 12, Issue 13, 2011, Pages 1258-1266

  Kridel, Robert ^a   Dietrich, Pierre Yves ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BLEOMYCIN SULFATE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROXYUREA; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

BCL2 GENE; BRAIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; GENE EXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; NOTE; ONCOGENE; ONCOGENE MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 82555179236     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70140-1     Document Type: Note

References (76)

1. Swerdlow SH, Campo E, Lee Harris N, et al. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues 2008, IARC Press, Lyon.
2. Pfreundschuh M Therapy of diffuse large B-cell lymphomas. Eur J Cancer 2009, 45(suppl 1):386-387.
3. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
4. Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin Oncol 2009, 36(suppl 2):S25-S34.
5. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 2000, 11:685-690. for the Groupe d'Etudes des Lymphomes de l'Adulte.
6. Feugier P, Virion J, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004, 15:129-133.
7. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007, 18:149-157.
8. Bjorkholm M, Hagberg H, Holte H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007, 18:1085-1089.
9. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009, 113:3896-3902.
10. Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group. J Clin Oncol 2009, 27:114-119.
11. Hegde U, Filie A, Little R, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005, 105:496-502.
12. Di Noto R, Scalia G, Abate G, et al. Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas. Leuk Res 2008, 32:1196-1199.
13. Quijano S, Lopez A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009, 27:1462-1469.
14. Hill Q, Owen R CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006, 20:319-332.
15. Kwong Y, Yeung D, Chan J Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 2009, 88:193-201.
16. Cortes J, O'Brien S, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995, 86:2091-2097.
17. Blum K, Lozanski G, Byrd J Adult Burkitt leukemia and lymphoma. Blood 2004, 104:3009-3020.
18. National Comprehensive Cancer Network guidelines for treatment of cancer by site: non-Hodgkin's lymphoma National Comprehensive Cancer Network, (accessed May 1, 2011). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
19. Tilly H, Dreyling M Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v172-v174.
20. Buckstein R, Lim W, Franssen E, Imrie K CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma 2003, 44:955-962.
21. Cheung C, Burton C, Smith P, et al. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 2005, 131:193-200.
22. Kumar A, Vanderplas A, LaCasce AS, et al. Incidence, method and covariates of central nervous system (CNS) prophylaxis for diffuse large B-cell lymphoma in the National Comprehensive Cancer Network (NCCN) lymphoma database. ASH Annual Meeting; Orlando, FL; Dec 4-7, 2010. I-736.
23. Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002, 13:1099-1107.
24. Shimazu Y, Notohara K, Ueda Y Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009, 89:577-583.
25. Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010, 21:1046-1052.
26. Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 2010, 85:6-10.
27. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 2011, published online Jan 13. 10.1007/s00277-010-1150-7.
28. Zucca E, Conconi A, Mughal T, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003, 21:20-27.
29. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011, 29:1452-1457.
30. Avilés A, Delgado S, Nambo MJ, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005, 69:256-260.
31. Van Besien K, Ha C, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998, 91:1178-1184.
32. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
33. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
34. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
35. Montesinos-Rongen M, Brunn A, Bentink S, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 2008, 22:400-405.
36. Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006, 107:190-196.
37. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011, 117:2319-2331.
38. Savage K, Johnson N, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009, 114:3533-3537.
39. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
40. Lopez-Giral S, Quintana N, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 2004, 76:462-471.
41. Smith J, Braziel R, Paoletti S, et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003, 101:815-821.
42. Jahnke K, Coupland SE, Na I-K, et al. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. Blood 2005, 106:384-385.
43. Chua S, Seymour J, Streater J, et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002, 43:1783-1788.
44. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer 2002, 95:576-580.
45. Arkenau H-T, Chong G, Cunningham D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007, 18:541-545.
46. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003, 102:4284-4289.
47. Fisher R, Gaynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
48. Coiffier B, Gisselbrecht C, Herbrecht R, et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989, 7:1018-1026.
49. Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994, 12:2543-2551. for the Groupe d'Etude des Lymphomes de l'Adulte.
50. Tilly H, Mounier N, Lederlin P, et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. J Clin Oncol 2000, 18:1309-1315. for the Groupe d'Etudes des Lymphomes de l'Adulte.
51. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
52. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004, 104:626-633.
53. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 2002, 20:4413-4419.
54. Schmitz N, Zeynalova S, Glass B, et al. CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT). ASH Annual Meeting; Orlando, FL; Dec 4-7, 2010. 112.
55. Glass B, Kloess M, Bentz M, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006, 107:3058-3064.
56. Schmitz N, Nickelsen M, Ziepert M, et al. Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young, high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). ASH Annual Meeting; New Orleans, LA, USA; Dec 5-8, 2009. 404.
57. Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010, 116:4283-4290.
58. Sehn L, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
59. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
60. Habermann T, Weller E, Morrison V, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
61. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
62. Rubenstein J, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003, 101:466-468.
63. Fleischhack G, Jaehde U, Bode U Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 2005, 44:1-31.
64. Glantz M, LaFollette S, Jaeckle K, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110-3116.
65. Chamberlain M Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 1998, 38:135-140.
66. Shapiro W, Young D, Mehta B Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975, 293:161-166.
67. Chamberlain M, Kormanik P, Glantz M A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 2001, 3:42-45.
68. Glantz M, Cole B, Glantz L, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998, 82:733-739.
69. Rogers L, Duchesneau P, Nunez C, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992, 42:1239-1241.
70. Blasberg R, Patlak C, Fenstermacher J Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975, 195:73-83.
71. Perissinotti A, Reeves D Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother 2010, 44:1633-1640.
72. Smith JA, Glantz M Statistical and trial design considerations in central nervous system prophylaxis studies. Semin Oncol 2009, 36(suppl 2):S69-S76.
73. Niemann A, Mühlisch J, Frühwald MC, et al. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?. Ther Drug Monit 2010, 32:467-475.
74. Vassal G, Valteau D, Bonnay M, et al. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma. Pediatr Hematol Oncol 1990, 7:71-77.
75. Beauchesne P Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 2010, 11:871-879.
76. Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M Response: intrathecal methotrexate and central nervous system events. Blood 2009, 114:1999-2000.